Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double-blind randomized Phase II udenafil dose-ranging study in portal hypertension due to liver cirrhosis
2006-006393-14Phase 3Completed
- Sponsor
- Dr. Falk Pharma GmbH
- Start
- May 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of udenafil in Portal Hypertension (PH) and Cirrhosis (4 arms), sponsored by Dr. Falk Pharma GmbH. Primary endpoint: Change in hepatic venous pressure gradient (HVPG). Started May 2007; status: completed.
02
Drugs
udenafil
03
Conditions
Portal Hypertension (PH)Cirrhosis
Beyond the preview
Go deeper on 2006-006393-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006393-14.